Why the study?
Does implantable cardioverter defibrillator (ICD) implantation reduce mortality in patients with heart failure and EF≤35%?
Does implantable cardioverter defibrillator (ICD) implantation reduce mortality in patients with heart failure and EF≤35%?
Answers are grounded in this paper and cite their sources.
ICDs are significantly underutilized in eligible heart failure patients (EF≤35%) primarily due to lack of physician discussion, despite being associated with lower mortality.
BACKGROUND: Despite ACC/AHA guidelines indicating implantable cardioverter defibrillator (ICD) as class I therapy for primary prevention of sudden cardiac death in patients with EF≤35%, ICD utilization rates in real world practice have been low. OBJECTIVE: To determine the rate of ICD implantation at a tertiary care academic center and to assess the reasons for under-utilization of the same. METHODS: Review of a prospectively collected database which included all patients diagnosed with an EF≤35% was performed to assess the rate of ICD implantation and mortality. Reasons for non-implantation of ICD were then assessed from detailed chart review. RESULTS: A total of 707 patients (age 69.4 ± 14.1 years) with mean EF of 26±7% were analyzed. Only 28% (200/707) of patients had ICDs implanted. Mortality was lower in the group with ICD (25% vs 37%, p=0.004). When patients who either died or were lost to follow-up prior to 2005 were excluded, ICD utilization rate was still low at 37.6%. The most common reason for non-implantation of ICD was physicians not discussing this option with their patients. Patient refusal was the second most common reason. CONCLUSIONS: ICD Implantation rates for primary prevention of SCD in patients with EF≤35% is low. Physician and patient education should be addressed to improve the utilization rates.
No takes yet. Share an insight, caveat, or question.
Pillarisetti et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: